loading page

Post-Transplant Lymphoproliferative Disorder (PTLD) Associated EBV Viremia After Liver Transplantation in Children: Experience from Single Center
  • +8
  • Dogan Barut,
  • Miray Karakoyun,
  • Sema Yildirim Arslan,
  • Bora Kunay,
  • Veysel Umman,
  • Benan Dernek,
  • Ezgi Kıran Taşçı,
  • Gözde Akkuş Kayalı,
  • Zumrut Bal,
  • Funda Cetin,
  • Aydogdu Sema
Dogan Barut
Ege Universitesi Dahili Tip Bilimleri Bolumu
Author Profile
Miray Karakoyun
Ege Universitesi Dahili Tip Bilimleri Bolumu

Corresponding Author:[email protected]

Author Profile
Sema Yildirim Arslan
Ege Universitesi Dahili Tip Bilimleri Bolumu
Author Profile
Bora Kunay
Ege Universitesi Dahili Tip Bilimleri Bolumu
Author Profile
Veysel Umman
Ege Universitesi Dahili Tip Bilimleri Bolumu
Author Profile
Benan Dernek
Ege Universitesi Dahili Tip Bilimleri Bolumu
Author Profile
Ezgi Kıran Taşçı
TC Saglik Bakanligi Sivas Numune Hastanesi
Author Profile
Gözde Akkuş Kayalı
Ege Universitesi Dahili Tip Bilimleri Bolumu
Author Profile
Zumrut Bal
Ege Universitesi Dahili Tip Bilimleri Bolumu
Author Profile
Funda Cetin
Ege Universitesi Dahili Tip Bilimleri Bolumu
Author Profile
Aydogdu Sema
Ege Universitesi Dahili Tip Bilimleri Bolumu
Author Profile

Abstract

Objective: The most prevalent malignancy that complicates both adult and pediatric solid organ transplantation is post-transplant lymphoproliferative disorder (PTLD). This study aimed to analyze the clinical and pathological characteristics, treatments, and outcomes of EBV viremia and PTLD in pediatric liver transplant recipients. Method: A retrospective chart review was performed on 112 patients less than 18 years of age who underwent isolated orthotopic liver transplantation (OLT) between 2010 and 2022 at Ege University Children’s Hospital. Data gathered for 1-year post-OLT included age at OLT, EBV, immunoglobulin (Ig)M/IgG status of the donor and recipient, indication for OLT, induction regimen, all immunosuppression levels, date and result of EBV polymerase chain reaction (PCR) testing, rejection episodes documented by liver biopsy, and the development of PTLD. Result: Forty-nine patients (43.75%) developed EBV viremia (median interval from surgery: two months, min-max 2-36), of which 43 (87.8%) grafts came from living donors, and 6 (12.2%) came from deceased donors. Nine (18.4%) patients died during follow-up, and eight (16.3%) developed PTLD. Five patients developed EBV-related disease; one child developed hemophagocytic lymphohistiocytosis; one developed aplastic anemia; and one child developed B cell lymphoma. When PTLD patients and without-PTLD patients were compared, pediatric intensive care unit hospitalization, abnormal bone marrow biopsy findings, lymphadenopathy, age at diagnosis of EBV viremia, EBV viral load, tacrolimus (FK 506) pre-infection, and 1-month levels were higher in patients with PTLD (p<0.05). In logistic regression analysis, we showed that the age at diagnosis of EBV viremia was significantly higher in children with PTLD (p=0.045; OR, 1.389; 95% CI, 1.007-1.914). Discussion PTLD is a rare but severe complication associated with EBV after OLT. This study demonstrated that PTLD is associated with older age, higher tacrolimus blood levels before EBV viremia, at one month of EBV viremia, and higher peak EBV viral load.